CompletedNot Applicable

Research on New Diagnosis and Treatment Technologies for Early Lung Cancer

China92 participantsStarted 2023-08-01

Plain-language summary

To verify the clinical effectiveness and safety of the airway tree navigation system constructed by artificial intelligence (AI) in the navigation diagnosis of peripheral pulmonary nodules (PPLs).

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Aged 18 years or above.
✓. Patients with one or more peripheral lung nodules suspected to be lung cancer or poorly absorbing lesions on conventional anti-infective therapy.
✓. Patients with nodule diameters ≤30 mm (diameters mentioned in the text are the average of the maximum and minimum diameters).
✓. The nodules were pure ground glass nodules, partially solid nodules, or solid nodules.
✓. The nodule is surrounded by lung parenchyma and is not visible in the bronchial lumen above the segment.

Exclusion criteria

✕. Preoperative judgment that it is difficult for the patient to benefit from bronchoscopic biopsy (e.g., high risk of bleeding due to perivascular encasement of the lesion, difficulty in reaching the airway adjacent to the lesion due to previous lung surgery, etc.).
✕. Those with incomplete clinical data.
✕. Those with missing visits after biopsy.

What they're measuring

Diagnostic positive yield

Timeframe: One month after the patients were enrolled

Trial details

NCT IDNCT07000721

SponsorJisong Zhang

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-12-31

View on ClinicalTrials.gov More Lung Cancer, Peripheral Pulmonary Nodules trials